Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study by Naci, H. & Ioannidis, J. P. A.
  
Huseyin Naci 
Comparative effectiveness of exercise and 
drug interventions on mortality outcomes: 
metaepidemiological study 
 
Article (Published version) 
(Refereed) 
 
 
 
 
Original citation: 
Naci, H. and Ioannidis, J. P. A. (2013) Comparative effectiveness of exercise and drug 
interventions on mortality outcomes: metaepidemiological study. BMJ, 347 (oct01 ). f5577-f5577. 
ISSN 1756-1833 
 
DOI: 10.1136/bmj.f5577  
 
© 2013 CC BY-NC 3.0 
 
This version available at: http://eprints.lse.ac.uk/54278/ 
 
Available in LSE Research Online: November 2013 
 
LSE has developed LSE Research Online so that users may access research output of the 
School. Copyright © and Moral Rights for the papers on this site are retained by the individual 
authors and/or other copyright owners. Users may download and/or print one copy of any 
article(s) in LSE Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities 
or any commercial gain. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE 
Research Online website.  
Comparative effectiveness of exercise and drug
interventions on mortality outcomes:
metaepidemiological study
OPEN ACCESS
Huseyin Naci researcher 1 fellow 2, John P A Ioannidis director 3
1LSE Health, London School of Economics and Political Science, London, UK; 2Drug Policy Research Group, Department of Population Medicine,
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; 3Stanford Prevention Research Center, Stanford University
School of Medicine, Stanford, CA, USA
Abstract
Objective To determine the comparative effectiveness of exercise versus
drug interventions on mortality outcomes.
Design Metaepidemiological study.
Eligibility criteria Meta-analyses of randomised controlled trials with
mortality outcomes comparing the effectiveness of exercise and drug
interventions with each other or with control (placebo or usual care).
Data sourcesMedline and Cochrane Database of Systematic Reviews,
May 2013.
Main outcome measure Mortality.
Data synthesisWe combined study level death outcomes from exercise
and drug trials using random effects network meta-analysis.
ResultsWe included 16 (four exercise and 12 drug) meta-analyses.
Incorporating an additional three recent exercise trials, our review
collectively included 305 randomised controlled trials with 339 274
participants. Across all four conditions with evidence on the effectiveness
of exercise on mortality outcomes (secondary prevention of coronary
heart disease, rehabilitation of stroke, treatment of heart failure,
prevention of diabetes), 14 716 participants were randomised to physical
activity interventions in 57 trials. No statistically detectable differences
were evident between exercise and drug interventions in the secondary
prevention of coronary heart disease and prediabetes. Physical activity
interventions were more effective than drug treatment among patients
with stroke (odds ratios, exercise v anticoagulants 0.09, 95% credible
intervals 0.01 to 0.70 and exercise v antiplatelets 0.10, 0.01 to 0.62).
Diuretics were more effective than exercise in heart failure (exercise v
diuretics 4.11, 1.17 to 24.76). Inconsistency between direct and indirect
comparisons was not significant.
Conclusions Although limited in quantity, existing randomised trial
evidence on exercise interventions suggests that exercise and many
drug interventions are often potentially similar in terms of their mortality
benefits in the secondary prevention of coronary heart disease,
rehabilitation after stroke, treatment of heart failure, and prevention of
diabetes.
Introduction
Physical activity has well documented health benefits.1
Population level cohort studies have shown that people who
exercise enjoy a higher quality of life and improved health status
comparedwith those with sedentary behaviours, with subsequent
reductions in their risk of adverse outcomes such as admissions
to hospital. Randomised controlled trials have shown similarly
favourable findings in arthritis,2 cancer,3 4 diabetes,5 heart
disease,6 and respiratory illnesses,7 among other chronic
conditions.8 9 Large scale observational studies have also
established a clear association between exercise and all cause
mortality.10-12 Given the overwhelming evidence in support of
the health benefits of exercise,13 the Global Burden of Disease
study has recently ranked physical inactivity as the fifth leading
cause of disease burden in western Europe, and as one of the
top modifiable risk factors along with smoking.14
Despite recent calls to encourage physical activity as a strategy
to ward off the emerging burden of chronic conditions, including
heart disease and diabetes,15 population level physical activity
measures are discouraging. In the United Kingdom, only 14%
of adults exercise regularly, with roughly one third of adults in
England meeting recommended levels of physical activity.16 In
contrast, utilisation rates of prescription drugs continue to rise
sharply, increasing to an average of 17.7 prescriptions for every
person in England in 2010, compared with 11.2 in 2000.17
Abundant evidence from randomised controlled trials shows
the mortality benefits of certain drugs such as simvastatin in
the secondary prevention of cardiovascular disease,18 which is
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the most widely prescribed drug in the United Kingdom.
Research on themortality benefits of exercise, however, remains
primarily observational with a limited number of randomised
trials in select treatment areas.19More importantly, evidence on
how physical activity interventions fare compared with drug
interventions in reducing the risk of all cause mortality is
lacking.
We performed a comprehensive review of published
meta-analyses on topics with randomised trial evidence on both
exercise and drug interventions. For each condition, we
combined the data from multiple pairwise meta-analyses in
network meta-analyses to assess the geometry of the existing
evidence and to determine the comparative effectiveness of drug
and exercise interventions in reducing the risk of mortality.
Methods
Identification of relevant evidence
We used three steps to identify the relevant body of evidence.
Firstly, we searched Medline for meta-analyses of randomised
controlled trials evaluating the effectiveness of exercise based
interventions on mortality outcomes. Our search strategy
included terms for exercise interventions (exercise OR physical
activity), mortality outcomes (mortality OR death OR survival),
and meta-analysis of randomised controlled trials (randomized
OR meta-analysis) in the title, abstract, or keywords (latest
search 11 December 2012).
Secondly, for all conditions with evidence on the effectiveness
of exercise interventions on mortality outcomes, we identified
meta-analyses that evaluated the impact of specific drug
interventions on mortality outcomes. We identified the list of
relevant drug interventions using clinical practice guidelines,
developed by respective European and US clinical specialty
organisations (for example, American Heart Association,
European Society of Cardiology). In cases where clinical
practice guidelines did not give clear guidance around indicated
drug treatments, we consulted the US National Library of
Medicine’s Medline Plus website (www.nlm.nih.gov/
medlineplus/). For each drug of interest we searched the
Cochrane Database of Systematic Reviews to identify the most
up to date meta-analysis. In cases where Cochrane reviews did
not exist, we searched Medline using terms for drug names,
mortality outcomes (mortality OR death OR survival), and
meta-analysis of randomised controlled trials (randomized OR
meta-analysis).
Finally, we developed a separate search strategy in Medline to
identify randomised head to head comparisons of exercise versus
drug interventions (and their meta-analyses) for all conditions
with evidence on the effectiveness of exercise interventions on
mortality outcomes. The objective of this search was to capture
additional recent trials of exercise versus control intervention
that were not included in the meta-analyses evaluating the
effectiveness of exercise based interventions on mortality
outcomes. This search included terms for exercise interventions
(exercise OR physical activity), mortality outcomes (mortality
OR deathOR survival), and Cochrane Collaboration’s sensitivity
and precision maximising terms for randomised controlled trials
(latest search 27 May 2013).20
In all three steps we selected the most recent review if more
than one eligible meta-analysis was published for a given
condition or disease and for each particular intervention. We
considered studies embedded within meta-analyses (or single
studies identified in the third step) to be eligible for inclusion
if they were randomised controlled trials comparing the
effectiveness of exercise and drug interventions with another
or with control (placebo or usual care) on mortality outcomes.
Data extraction
From each eligible trial we extracted the publication year,
condition, number of participants, and number of deaths in each
trial arm. In cases where mortality outcomes were reported at
multiple time points, we selected the longest follow-up duration.
One investigator (HN) extracted data and another (Anthony J
Damico) checked for accuracy.
Evaluation of the geometry of evidence
We developed network diagrams to visualise the geometry of
the available evidence21 22; that is, the frequency of comparisons
between exercise and drug interventions to show the distribution
of trial participants across different treatment modalities (and
control). In each network diagram, the size of the nodes was
proportional to the number of participants receiving a given
intervention (or control), and the thickness of the lines
connecting the nodes was proportional to the number of
randomised participants in the trials between interventions. We
developed two sets of network diagrams. In the first we
compared exercise to all identified classes of drugs. In the
second we pooled all drug interventions into one group to show
the relative size of the patient population included in the trials
of exercise versus drug interventions.
Statistical analysis
We first qualitatively summarised included trials, describing
the types of direct and indirect comparisons. For each direct
comparison between two treatments we conducted pairwise
meta-analyses using the DerSimonian-Laird (random effects)
method,23 and statisticaly inspected heterogeneity using the I2
measure. We used rough I2 thresholds of 25%, 50%, and 75%
to define low (<25%), moderate (25-49%), high (50-75%), and
very high (>75%) heterogeneity. To determine the comparative
effectiveness of exercise and drug interventions, we then
conducted network meta-analysis, which is a generalisation of
indirect comparisons across pairwise meta-analyses.24 This type
of analysis allows for comparing interventions in the absence
of head to head trials comparing all the interventions of interest.25
In cases where both direct (from trials that include a specific
pairwise comparison) and indirect (from a network of trials that
do not include that comparison) sources of evidence exist,
network meta-analysis is capable of simultaneously combining
both types of evidence. This analysis preserves the within trial
randomised treatment comparison of each trial while combining
all available comparisons between treatments.
We combined study level relative treatment effects using
bayesian Markov chain Monte Carlo methods in WinBUGS
version 1.4.3. We used the model developed by Dias and
colleagues for the UK National Institute for Health and Care
Excellence Decision Support Unit.26 27 Our models adopted
random effects, taking into account potential heterogeneity by
assuming that each treatment was drawn from the same
distribution, the mean and variance of which were estimated
from the data.28 We also performed fixed effect analyses under
the assumption that no between study heterogeneity existed.29
Our model selection was based on two criteria. Firstly, we
evaluated the deviance information criterion between the two
sets of analyses, which favoured random effects models.
Secondly, we qualitatively judged the fixed effect model
assumption to be too strong given the potential differences in
patient populations across drug and exercise trials.25
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We statistically evaluated the consistency of direct and indirect
evidence in network meta-analyses using the Bucher method.30
This method, commonly used to investigate potential
inconsistency in evidence networks,31 32was based on conducting
random effects pairwise meta-analyses on all comparisons and
calculating the difference in log odds ratios between direct and
indirect estimates for each closed loop of the network (that is,
in all instances where both direct and indirect comparisons could
be generated for each contrast in the network).
We reported our findings in terms of odds ratios. The difference
between treatments was assessed on the basis of 95% credible
intervals. Such intervals can be interpreted as indicating a 95%
probability that the true odds ratio falls within the reported
range. If a 95% credible interval does not include the null value
1.00, this can be interpreted as indicating <5% probability that
there is no difference between the two comparators. Given the
bayesian nature of the statistical analyses, we neither estimated
nor reported P values for the network meta-analyses.
Primary analyses were at the intervention level, comparing
exercise with all relevant drug interventions for a given
condition. In a separate analysis we also pooled the drugs and
estimated the comparative effectiveness of exercise versus all
drug interventions. The analyses were based on the total number
of participants per trial arm, as reported in the identified
meta-analyses.
Results
Eligible meta-analyses
Our electronic search of exercise meta-analyses retrieved 225
titles and abstracts (fig 1⇓). After exclusions, we included four
meta-analyses of exercise interventions reporting mortality
outcomes (see supplementary table). One meta-analysis
evaluated the effectiveness of exercise interventions for the
secondary prevention of coronary heart disease,33 one for
stroke,34 one for heart failure,35 and one for prediabetes.36
In addition we separately identified 12 meta-analyses of drug
interventions (out of 534 titles and abstracts inMedline), which
were considered to be relevant drug options for each of the four
conditions that had evidence on exercise interventions: statins,18
β blockers,37 angiotensin converting enzyme inhibitors,38 and
antiplatelets for the secondary prevention of coronary heart
disease39; anticoagulants40 and antiplatelets41 for stroke42;
angiotensin converting enzyme inhibitors,43 diuretics,44 β
blockers,45 and angiotensin receptor blockers for heart failure46;
α glucosidase inhibitors, thiazolidinediones, biguanides,
angiotensin converting enzyme inhibitors, and glinides for
prediabetes.36 Publication dates for meta-analyses of drug
interventions ranged from 1999 to 2013 (see supplementary
table).
Most of the meta-analyses of drug interventions were placebo
controlled. However, one meta-analysis included direct head to
head trials comparing anticoagulants with antiplatelets for the
treatment of stroke,47 and one meta-analysis included a direct
comparison between angiotensin receptor blockers and
angiotensin converting enzyme inhibitors for the treatment of
heart failure.46 Similarly, the meta-analysis on prediabetes
included not only the placebo controlled trials of drug and
exercise interventions but also their direct head to head
comparisons.36
In total, our original search identified 16 (four exercise and 12
drug) meta-analyses, including 54 exercise trials and 248 drug
trials. Our separate electronic search in Medline, which yielded
2964 abstracts and titles, did not identify any additional direct
head to head trials of exercise and drug interventions evaluating
mortality outcomes for coronary heart disease, stroke, heart
failure, and prediabetes. This search captured 31 of the 54
exercise trials that were already included in the four exercise
meta-analyses. It also captured another three recent trials of
exercise versus control intervention published between 2008
and 2012 (total sample size 2041) that had not been included
in the four meta-analyses. Including these three exercise trials
in the analysis, our meta-epidemiological review collectively
included 305 randomised controlled trials with 339 274
participants. Of those, 57 trials concerned exercise interventions,
including 14 716 participants.
Characteristics of exercise interventions
The characteristics of the exercise interventions varied across
treatment areas. Differences included the mode of physical
activity and its frequency, intensity, and duration. Exercise
based cardiac rehabilitation was typically a component of
comprehensive cardiac care of patients with coronary heart
disease.33 Rehabilitation in this population included inpatient,
outpatient, community based, or home based exercise
interventions. Patients with stroke received a mix of
cardiorespiratory and muscle strengthening exercises.34
Similarly, exercise interventions targeting patients with chronic
heart failure included aerobic and resistance training.35 Physical
activity was often a component of multifactorial lifestyle
modification interventions to prevent diabetes among people
with impaired glucose tolerance and impaired fasting
glucose—that is, prediabetes.36
Comparability of trial and patient population
characteristics
Conceptual heterogeneity between drug and exercise trials was
minimal among patients with coronary heart disease (about
60-100% of patients had myocardial infarctions), heart failure
(patients were predominantly NewYork Heart Association class
II-IV), and prediabetes (patients had impaired glucose tolerance
and impaired fasting glucose with a balanced profile of obesity
and cardiovascular disease risk factors across exercise and drug
trials). However, the baseline disease severity of patient
populations was considerably different in stroke trials. While
survivors participating in drug trials were within two weeks of
onset of stroke, patients included in exercise trials were
predominantly ambulatory and could be up to 150 days after
stroke.
In all four conditions, trial characteristics varied for eligibility
criteria, follow-up duration, and blinding of participants,
investigators, and assessors (see supplementary table). In
general, variability within pairwise meta-analyses was greater
than between exercise and drug interventions. Statistical
variability in effect sizes was low in the majority of pairwise
meta-analyses, with moderate between study heterogeneity
present in the trials of angiotensin converting enzyme inhibitors
in the secondary prevention of coronary heart disease (I2=40%),
trials of β blockers in heart failure (I2=34%), and trials
comparing angiotensin receptor blockers with angiotensin
converting enzyme inhibitors in heart failure (I2=39%).
Geometry of available evidence
In all four conditions, relatively few participants were
randomised to exercise interventions compared with the
available evidence on drugs. Thirty four trials concerned exercise
interventions in the secondary prevention of coronary heart
disease (n=10 984 participants) compared with 43 trials of statins
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(n=55 151), 80 of β blockers (n=53 456), 15 of angiotensin
converting enzyme inhibitors (n=15 104), and 27 of antiplatelets
(n=38 076). No direct head to head trials compared any of the
drug or exercise interventions in the identified meta-analyses,
resulting in a star shaped evidence network for the secondary
prevention of coronary heart disease (fig 2⇓).
Three trials concerned exercise interventions among patients
with stroke (n=227) compared with 10 trials of anticoagulants
(n=22 786), 14 of antiplatelets (n=43 041), and three directly
comparing anticoagulants with antiplatelets (n=11 567, fig 2).
In the case of heart failure, 18 trials concerned exercise
interventions (n=3669) compared with five trials of angiotensin
converting enzyme inhibitors (n=12 763), three of diuretics
(n=202), 21 of β blockers (n=23 122), 11 of angiotensin receptor
blockers (n=11 795), and eight directly comparing angiotensin
receptor blockers with angiotensin converting enzyme inhibitors
(fig 2).
Two trials were of exercise interventions among participants
with prediabetes (n=1081 participants). In comparison, one trial
was of α glucosidase inhibitors (n=1368), one of
thiazolidinediones (n=407), two of angiotensin converting
enzyme inhibitors (n=14 575), and one of glinides (n=9306).
One trial directly compared exercise with α glucosidase
inhibitors (n=1778), and two multiarm trials including 3615
participants compared exercise, biguanides, and control (fig 2).
When the drug trials were pooled, 5685 participants with
coronary heart disease were randomised to exercise compared
with 85 421 randomised to control and 81 655 to drug
interventions (fig 3⇓). In a similar fashion, considerably fewer
participants were randomised to physical activity interventions
in stroke trials (n=117), heart failure trials(n=1830), and
prediabetes trials (n=2491). Respective numbers of participants
randomised to drug interventions were 44 731, 30 024, and 14
867.
Comparative effectiveness of exercise and
drugs
In coronary heart disease the odds of mortality was reduced
with use of statins (odds ratio 0.82, 95% credible interval 0.75
to 0.90), β blockers (0.85, 0.78 to 0.92), angiotensin converting
enzyme inhibitors (0.83, 0.72 to 0.96), and antiplatelets (0.83,
0.74 to 0.93) compared with control, whereas exercise
interventions had a similar point estimate but wider credible
intervals that extended on both sides of 1.00 (odds ratio 0.89,
95% credible interval 0.76 to 1.04, fig 4⇓). When compared
head to head in network meta-analyses, all interventions were
not different beyond chance: there were no statistically
detectable differences among any of the exercise and drug
interventions in terms of their effects on mortality outcomes
(tables 1⇓).
Unlike any of the drug interventions, exercise was significantly
more effective than control in reducing the odds of mortality
(0.09, 0.01 to 0.72) among patients with stroke (fig 4). When
compared head to head in network meta-analyses, exercise
interventions were more effective than anticoagulants (0.09,
0.01 to 0.70) and antiplatelets (0.10, 0.01 to 0.62), albeit with
considerable uncertainty owing to the small number of events
in exercise trials (table 2⇓). Anticoagulants were also marginally
worse than antiplatelets (1.11, 1.00 to 1.21).
In heart failure, fewer deaths occurred with diuretics (0.19, 0.03
to 0.66) and β blockers (0.71, 0.61 to 0.80) compared with
control (fig 3). Diuretics weremore effective than exercise (0.24,
0.04 to 0.85), angiotensin converting enzyme inhibitors (0.21,
0.03, 0.76), β blockers (0.27, 0.04 to 0.93), and angiotensin
receptor blockers (0.21, 0.03 to 0.73, table 3⇓). Angiotensin
receptor blockers were associated with more deaths compared
with β blockers (1.30, 1.02 to 1.61).
Neither exercise nor drug interventions were clearly effective
in reducing the odds of mortality in prediabetes (fig 4). There
were also no major detectable differences between any
comparator interventions (table 4⇓).
In secondary analyses comparing exercise with the drug
interventions pooled together, there was no definitive differences
between drug and exercise interventions in coronary heart
disease, heart failure, and prediabetes, but effect sizes had
modestly substantial uncertainty for heart failure and prediabetes
(table 5⇓). Although exercise interventions were more effective
than drugs in reducing the odds of mortality among patients
with stroke, this finding was associated with large uncertainty
in the exact estimate of the treatment effect owing to the small
number of events.
In all network meta-analyses with closed loops, there was no
statistically detectable inconsistency between direct and indirect
evidence (see supplementary table).
Discussion
This metaepidemiological study of 16 meta-analyses including
305 randomised controlled trials with 339 274 participants
highlights the near absence of evidence on the comparative
effectiveness of exercise and drug interventions on mortality
outcomes. Existing evidence on the mortality benefits of
physical activity is limited to the secondary prevention of
coronary heart disease, rehabilitation after stroke, treatment of
heart failure, and prevention of diabetes. Perhaps unsurprisingly,
the amount of evidence on the mortality benefits of exercise is
considerably smaller than that on drug interventions. There is
also a clear lack of exercise and drug comparisons: trials
evaluating the effectiveness of pharmacotherapy rarely included
physical activity as a comparator. Albeit this considerable
asymmetry in the evidence base, our analysis suggests that
exercise potentially had similar effectiveness to drug
interventions with two exceptions. In the case of stroke
rehabilitation, exercise seemed to be more effective than drug
interventions. In heart failure, diuretics outperformed all
comparators, including exercise. When the drug interventions
were considered together in sensitivity analyses, exercise and
drug interventions did not differ in terms of their mortality
benefits in all conditions except for stroke rehabilitation, where
exercise interventions were associated with a reduction in the
odds of mortality more than drug interventions.
Geometry of existing evidence
Evidence from randomised controlled trials on the mortality
benefits of exercise is scarce. Even in treatment areas where
such evidence exists, exercise trials evaluating mortality
outcomes were at a disadvantage in two ways: considerably
fewer trials evaluated exercise than drugs (57 out of 305 trials),
and fewer people participated in exercise trials (14 716 out of
339 274 participants).
Our findings reflect the bias against testing exercise
interventions and highlight the changing landscape of medical
research, which seems to increasingly favour drug interventions
over strategies to modify lifestyle. The current body of medical
literature largely constricts clinicians to drug options.48 This
blind spot in available scientific evidence prevents prescribers
and their patients from understanding the clinical circumstances
where drugs might provide only modest improvement but
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exercise could yield more profound or sustainable gains in
health. The lopsided nature of modern medical research may
fail to detect the most effective treatment for a given condition
if that treatment is not a prescription drug.
As the disparity between exercise based and drug based
treatment evidence has increased, clinical practice guidelines
have followed suit.49 50 For example, although earlier versions
of the United States’ national cholesterol education programme
guidelines advised the use of statins only after exhausting
interventions for intensive lifestyle modification for the
prevention of coronary heart disease in people with high
cholesterol levels,51 subsequent versions progressively lowered
the threshold for drug treatment and considerably expanded
both the scope and the intensity of drug treatment.52
Clinical practice implications of this study
The findings of our review suggest that exercise and many drug
interventions are often potentially similar in terms of their
mortality benefits; exercise interventions should therefore be
considered as a viable alternative to, or alongside, drug therapy.
Indeed, an increasing number of experts recommend prescribing
an “exercise pill” as a preventive strategy to reduce morbidity
and mortality.53 54 According to the US Centers for Disease
Control and Prevention, roughly one third of clinicians prescribe
exercise in primary care.55 However, as previous systematic
reviews have shown, there is considerable uncertainty as to the
effectiveness of primary care interventions for increasing
physical activity.56 57As previously recommended, primary care
doctors should give brief advice to most patients about the
benefits of exercise and refer patients with chronic disease to a
rehabilitation programme that includes an exercise intervention.58
Previous research has shown that patients with a variety of
chronic conditions can expect to improve their functional
capacity as well as muscle strength by a range of exercise
interventions.8 9Although we considered exercise interventions
as a group, a more nuanced consideration of the effectiveness
of different types of physical activity is warranted. Among the
four therapeutic conditions considered in our review, exercise
interventions varied in terms of their type, intensity, and
duration, highlighting the need to tailor exercise regimens for
individual patient circumstances, such as baseline disease
severity and mobility. The relative dearth of evidence leaves
substantial uncertainty on which patients would benefit more
from what type of exercise, and which forms of exercise may
not be effective in different settings.
Complicating matters further, the evidence on the potentially
harmful side effects of exercise interventions is limited.
Individual trials included in the meta-analyses did not report
adverse events associated with exercise interventions in a
systematic manner. Nevertheless, some existing information is
encouraging: according to a 10 year follow-up study of exercise
based rehabilitation of patients with heart failure, there were no
important adverse events requiring the interruption of any
training sessions.59 Indeed, authors of the Cochrane review on
exercise rehabilitation for heart failure found no evidence to
suggest that such programmes cause harm.35 Similarly, authors
of the Cochrane review on exercise training for stroke survivors
concluded that participation in exercise training programmes
seems to be safe.34 For the secondary prevention of coronary
heart disease, rates of adverse events in exercise rehabilitation
settings are low.60
Limitations of this study
Our findings should be interpreted in light of their limitations.
Firstly, although exercise seemed to be more effective than drug
interventions in stroke rehabilitation, and diuretics seemed to
be more effective than exercise interventions in heart failure
treatment, these findings should be interpreted with caution
given the scarceness of data and the different settings involved.
Although between study heterogeneity was generally low, with
no statistical evidence of inconsistency between direct and
indirect comparisons, it remains a possibility that potential
imbalances in the distribution of unobserved or unmeasured
effect modifiers across the contrasts affected the findings,61
potentially confounding the comparative estimates between
drugs and exercise. Accordingly, we caution that the comparison
of exercise and drug interventions should be tempered by the
additional differences in patient populations across different
trials.
Secondly, the definition of exercise interventions varied across
the list of included trials, limiting the generalisability of our
findings to different types of physical activity. Thirdly, several
meta-analyses of drug interventions were outdated and it was
logistically difficult to try to update somany drugmeta-analyses.
As a result, our reviewmay have underestimated the magnitude
of data available on drug interventions. Conversely, it is unlikely
that we missed substantial randomised trial data on exercise,
thus the relative dearth of evidence on exercise versus evidence
on drugs may be even more prominent. Our Medline search
identified only three new exercise trials,59 62 63 although it
captured 31 of the 54 older ones that had been included in
previous meta-analyses. Based on the capture-recapture
principle, we may have missed another two exercise trials
only—that is, 3×(54−31)/31. Overall, the evidence on the effects
of exercise is clearly outnumbered by the evidence on drugs.
Moreover, if anything, there is evidence that updated
meta-analyses tend to show smaller treatment effects,64 so the
benefits of some drug interventions may be overrated.
Fourthly, exercise trials often included some drug interventions
(although the details of drug treatments were limited), which
were given similarly to both the physical therapy and the usual
care arms, suggesting that the observed effect of exercise
possibly represented the added benefit of exercise over and
above the benefit conferred by drug interventions. This might
have underestimated the effectiveness of exercise on mortality,
according to the findings of recent research showing that statin
treatment may decrease the fitness benefits of exercise.65
As an overview of published meta-analyses, our review also
shares the limitations of the existing evidence. Previous reviews
(and the randomised controlled trials on which they are based)
did not always make clear the settings in which physical
interventions were undertaken, how they were carried out, and
potential factors responsible for the success or failure of the
intervention. It is particularly important to characterise these
so-called “support factors” of exercise interventions in
randomised controlled trials (for example, extent of supervision,
individual level versus group level activity), which would allow
future researchers and practitioners to replicate successful
interventions and avoid unsuccessful ones.66
Future directions
Despite its limitations, this meta-epidemiological review is the
first to compare the mortality benefits of exercise and drug
interventions. This comprehensive look at the existing body of
evidence highlights the need to perform randomised trials on
the comparative effectiveness of exercise and drug interventions.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5577 doi: 10.1136/bmj.f5577 (Published 1 October 2013) Page 5 of 14
RESEARCH
Given the scarcity of financial resources to fund future trials of
exercise interventions, one option would be to require such
evidence from pharmaceutical companies that are under
increasing pressure to perform active-comparator trials for
market entry.67 68 For example, regulators should consider
requiring pharmaceutical sponsors of new drugs to include
exercise interventions as an active comparator arm in drug trials.
In cases where drug options provide only modest benefit,
patients deserve to understand the relative impact that physical
activity might have on their condition.
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What is already known on this topic
Population level cohort studies suggest that physical activity is associated with a decreased risk of mortality
A large number of randomised controlled trials show the mortality benefits of certain drug interventions
What this study adds
Evidence on the mortality benefits of drug and exercise interventions for common diseases varies widely, highlighting the paucity of
data on the effectiveness of exercise interventions in randomised trials
Based on available data on the secondary prevention of coronary heart disease, stroke, heart failure, and prediabetes, physical activity
is potentially as effective as many drug interventions
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Tables
Table 1| Findings of network meta-analyses: comparative effects of exercise and drug interventions on mortality outcomes in coronary
heart disease. Values are odds ratios (95% credible intervals)
Comparator drugsIntervention
AntiplateletsACE inhibitorsβ blockersStatins
1.07 (0.88 to 1.30)1.08 (0.87 to 1.33)1.05 (0.87 to 1.25)1.08 (0.90 to 1.30)Exercise
0.99 (0.85 to 1.15)0.99 (0.84 to 1.18)0.97 (0.85 to 1.10)—Statins
1.02 (0.89 to 1.17)1.03 (0.87 to 1.21)——β blockers
0.99 (0.83 to 1.19)———ACE inhibitors
ACE=angiotensin converting enzyme.
Estimates lower than 1.00 favour row defining intervention.
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Table 2| Findings of networkmeta-analyses: comparative effects of exercise and drug interventions onmortality outcomes in stroke. Values
are odds ratios (95% credible intervals)
Comparator drugs
Intervention AntiplateletsAnticoagulants
0.10 (0.01 to 0.62)0.09 (0.01 to 0.70)Exercise
1.11 (1.00 to 1.21)—Anticoagulants
Estimates lower than 1.00 favour row defining intervention.
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Table 3| Findings of network meta-analyses: comparative effects of exercise and drug interventions on mortality outcomes in heart failure.
Values are odds ratios (95% credible intervals)
Comparator drugs
Intervention ARBsβ blockersDiureticsACE inhibitors
0.86 (0.62 to 1.16)1.11 (0.82 to 1.46)4.11 (1.17 to 24.76)0.89 (0.59 to 1.23)Exercise
0.96 (0.78 to 1.27)1.24 (0.96 to 1.71)4.66 (1.32 to 28.21)—ACE inhibitors
0.21 (0.03 to 0.73)0.27 (0.04 to 0.93)——Diuretics
0.77 (0.62 to 0.98)———β blockers
ACE=angiotensin converting enzyme; ARBs=angiotensin receptor blockers.
Estimates lower than 1.00 favour row defining intervention.
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Table 4| Findings of network meta-analyses: comparative effects of exercise and drug interventions on mortality outcomes in prediabetes.
Values are odds ratios (95% credible intervals)
Comparator drugs
Intervention GlinidesACE inhibitorsBiguanidesAGIs
0.69 (0.10 to 2.52)0.73 (0.14 to 1.96)2.67 (0.41 to 36.39)0.22 (0.02 to 1.18)Exercise
3.06 (0.33 to 48.01)3.26 (0.42 to 43.94)13.39 (0.99 to 519.75)—AGIs
0.25 (0.01 to 2.08)0.26 (0.01 to 1.85)——Biguanides
0.93 (0.18 to 5.49)———ACE inhibitors
AGIs=α glucosidase inhibitors; ACE=angiotensin converting enzyme.
Estimates lower than 1.00 favour row defining intervention.
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Table 5| Findings of network meta-analyses: comparative effects of exercise and all drug interventions on mortality outcomes in coronary
heart disease, stroke, heart failure, and prediabetes
Odds ratio (95% CrI) drugs v exerciseTreatment area
0.94 (0.80 to 1.11)Coronary heart disease
8.66 (1.28 to 245.10)*Stroke
0.99 (0.73 to 1.36)Heart failure
1.43 (0.81 to 3.11)Prediabetes
Estimates lower than 1.00 favour drug interventions, estimates higher than 1.00 favour exercise.
*Odds ratio was associated with considerable uncertainty owing to extremely small numbers of events in exercise trials.
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Figures
Fig 1 Steps involved in study identification and selection
Fig 2 Network of available comparisons between exercise and individual drug interventions in coronary heart disease,
stroke, heart failure, and prediabetes. Size of node is proportional to number of trial participants, and thickness of line
connecting nodes is proportional to number of participants randomised in trials directly comparing the two treatments.
ACE=angiotensin converting enzyme
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Fig 3 Network of available comparisons between exercise and all drug interventions in coronary heart disease, stroke,
heart failure, and prediabetes. Size of node is proportional to number of trial participants, and thickness of line connecting
nodes is proportional to number of participants randomised in trials directly comparing the two treatments
Fig 4 Findings of network meta-analysis: effects of exercise and drug interventions compared with control on mortality
outcomes in coronary heart disease, stroke, heart failure, and prediabetes. Results shown are odds ratios and 95% credible
intervals. Odds ratios lower than 1.00 favour intervention compared with control. ACE=angiotensin converting enzyme.
*Number of data points for thiazolidinediones was insufficient to obtain an estimate of odds ratio compared with control
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